Organização Mundial of Saúde confirmed that the BA.3.2 variant of the Covid-19 virus has already been identified in at least 32 countries. International health authorities indicate that so far there is no evidence that this strain causes more serious illness or completely escapes the protection of available vaccines. The lineage presents a high number of mutations in the Spike protein, but preliminary assessments do not indicate a significant increase in transmissibility or severity of cases.
The variant was initially detected in November 2024 in África of Sul. Desde then spread to other territories, with records in nations of África, Europa, Ásia, América, Norte and Oceania. The increase in detections gained pace from September 2025 onwards, especially in some European regions where it represented around 30% of the sequences analyzed in countries such as Dinamarca, Alemanha and Holanda during the months of November 2025 to January 2026.
- BA.3.2 is genetically distinct from the JN.1 lineages that circulated predominantly in 2024 and 2025.
- It accumulates approximately 70 to 75 substitutions and deletions in the Spike protein gene sequence compared to the strains used in current vaccines.
- By February 2026, the variant had already been officially reported in 23 countries, a number that has evolved to at least 32 with recent genomic surveillance updates.
Initial detection and global expansion
The first BA.3.2 sequence was obtained from a respiratory sample collected from a five-year-old child on África of Sul. Meses later, the strain appeared in Moçambique, followed by identifications in Holanda and Alemanha. Detections remained sporadic at first, but grew steadily from the second half of 2025 onwards.
Countries such as Estados Unidos, Reino Unido, No Brasil, to date there is no official confirmation of the circulation of this specific lineage. Genomic surveillance remains active in reference laboratories around the world to monitor possible changes in the behavior of the virus.
Genetic characteristics of the variant
BA.3.2 presents mutations mainly concentrated in the Spike protein, responsible for the virus’s entry into human cells. Esse set of changes gives the strain substantial immune escape potential in relation to previous infections or vaccine-induced immunity. However, experts have so far not identified any evidence that it causes more severe clinical conditions.
Laboratory analyzes indicate that the variant does not demonstrate a clear advantage in sustained growth over other strains that circulate simultaneously. In some European countries, BA.3.2 reached relevant proportions in sequenced samples, but without notable impact on the total number of hospitalizations or deaths due to Covid-19.
Monitoring in Estados Unidos
In the Estados Unidos, the variant was identified in samples from international travelers, in airport wastewater and in sewage surveillance from multiple states. Até February 2026, 132 positive results were recorded in wastewater samples from 25 states, in addition to detections in patients and in clinical sequences. The general prevalence remained low, around 0.55% in samples analyzed between December 2025 and March 2026.
Multimodal surveillance, which combines genomic sequencing, traveler monitoring and wastewater analysis, made it possible to detect BA.3.2 early. Autoridades Americans maintain continuous monitoring to assess any changes in the virus circulation pattern.
WHO assessment of public health risk
Organização Mundial of Saúde classifies BA.3.2 as a variant under monitoring. Available assessments indicate that current vaccines and antiviral treatments should continue to offer protection against severe forms of the disease, even with partial escape observed in laboratory tests. Não there are records of a significant increase in the transmission rate or lethality associated with this strain.
Experts reinforce the importance of continuing global genomic surveillance. Países with limited sequencing capacity may underreport the presence of the variant, which requires international collaboration to map its actual distribution.
Recent Surveillance Updates
New BA.3.2 sublineages were identified through phylogenetic analyses, demonstrating that the virus continues to evolve. Detections in wastewater and travelers serve as an early signal for public health systems. In regions where BA.3.2 gained a greater proportion in the sequences, the general indices of Covid-19 did not exceed the levels observed in previous years.
The scientific community remains focused on comparing BA.3.2 and other dominant lineages. Até At the moment, there is no evidence that it has replaced strains in circulation as the main cause of cases.
Recommendations from health authorities
Public health bodies advise the maintenance of standard preventive measures, including updating vaccinations according to recommended schedules. Testing remains recommended for people with respiratory symptoms, especially in risk groups. The use of masks in closed or crowded environments remains a valid option depending on the local situation.
Continuous surveillance allows adjustments to be made quickly if relevant changes in the variant’s behavior emerge. Laboratórios international organizations share data to support decisions based on scientific evidence.
Genomic surveillance perspective
Monitoring BA.3.2 reinforces the need for robust sequencing systems on different continents. Early detection in multiple countries demonstrates the efficiency of global surveillance networks, even with the virus at endemic levels. Especialistas highlight that the evolution of SARS-CoV-2 follows an expected pattern, with the periodic emergence of new lineages.
BA.3.2 did not significantly change the current outlook for Covid-19. However, its presence in 32 countries serves as a reminder that the virus continues to circulate and mutate, justifying the maintenance of public health response capabilities.
Current situation at Brasil
To date, there are no confirmed records of the BA.3.2 variant in Brazilian territory. Local authorities maintain active surveillance through reference laboratories and genomic sequencing networks. Qualquer future detection will be communicated according to established protocols.
The population can continue to follow the general guidelines for preventing respiratory infections, such as hand hygiene and room ventilation.